3. Edwards Lifesciences ( EW) sells cardiovascular devices.

The numbers: Third-quarter profit more than doubled to $74 million, or $1.25 a share. Revenue advanced 7% to $326 million. The company's operating margin widened from 15% to 17%. Edwards has a liquid balance sheet, with $290 million of cash and $102 million of debt.

The stock: Edwards Lifesciences increased 58% in the past 12 months, more than major U.S. indices. The stock trades at a price-to-earnings ratio of 24, a discount to health-care-equipment peers. Edwards doesn't pay dividends.

If you liked this article you might like

Edwards Lifesciences: Cramer's Top Takeaways

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Edwards Lifesciences Is Not Skipping A Beat

Canaccord Says Edwards Lifesciences Is Its Favorite Med Tech Stock